Intrathecal substance P-saporin for the treatment of intractable cancer pain

Hugh Nymeyer, Douglas A. Lappi, Denise Higgins, Carl E. Noe, Arthur E. Frankel

Research output: Chapter in Book/Report/Conference proceedingChapter


Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

Original languageEnglish (US)
Title of host publicationTechniques of Neurolysis
PublisherSpringer International Publishing
Number of pages10
ISBN (Electronic)9783319276076
ISBN (Print)9783319276052
StatePublished - Jan 1 2016


  • Allodynia pain
  • Hyperalgesia
  • NK1
  • SP-SAP
  • Substance p

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Intrathecal substance P-saporin for the treatment of intractable cancer pain'. Together they form a unique fingerprint.

Cite this